Aradigm
HomeAboutProductsTechnologiesInvestorsCareers
Press Releases

Press Releases

All Releases
Aradigm Announces Exercise of Warrants for Proceeds of Approximately $891,000
Sep 23, 2010
All Warrants Issued in June 2010 Private Placement Are Exercised
Aradigm Closes Equity for Debt Transaction with Novo Nordisk A/S
Sep 20, 2010
$9.1 Million in Debt Extinguished in Exchange for 26 Million Shares of Common Stock
Aradigm Presents Results Supporting Once-Daily Dosing With Its Inhaled Liposomal Ciprofloxacin Formulations at the 2010 European Respiratory Society (ERS) Annual Congress
Sep 17, 2010
HAYWARD, Calif., Sep 17, 2010 (BUSINESS WIRE) -- Aradigm Corporation (OTCBB:ARDM) ("Aradigm") today announced it is presenting data on September 22, 2010, from its Phase 1 studies at the ERS Annual Congress in Barcelona, Spain. The podium presentation elaborates on the pharmacokinetic parameters of
Aradigm Announces Second Quarter 2010 Financial Results
Aug 12, 2010
Two Key Transactions Strengthen Balance Sheet - Company Raises $4.1M and Will Eliminate $9.1M in Debt
Aradigm Announces Equity for Debt Transaction with Novo Nordisk
Aug 02, 2010
$9.1 Million in Debt Extinguished in Exchange for 26 Million Shares of Common Stock
Aradigm Announces Private Placement for $5 Million
Jun 21, 2010
Proceeds Will Further Development of Inhaled Liposomal Ciprofloxacin for the Treatment of Severe Respiratory Diseases
Aradigm Presents at the 2010 International Conference of the American Thoracic Society
May 17, 2010
Unique Pharmacokinetic Profile and Good Tolerability was Demonstrated for ARD-3150
Aradigm Announces First Quarter 2010 Financial Results
May 13, 2010
Milestone Receipt and Expense Reduction Efforts Significantly Reduce Net Loss
Aradigm Receives FDA Clearance for Clinical Trial of Inhaled Liposomal Ciprofloxacin in Pediatric Patients With Cystic Fibrosis
May 05, 2010
HAYWARD, Calif., May 05, 2010 (BUSINESS WIRE) -- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced it received clearance from the U.S. Food and Drug Administration (FDA) for its inhaled liposomal ciprofloxacin Investigational New Drug (IND) application.
Aradigm Completes Enrollment and Doses Last Patient in Long Term Phase 2 Study of a Novel Inhaled Ciprofloxacin Formulation for the Management of Respiratory Infections in Bronchiectasis
Mar 25, 2010
HAYWARD, Calif., Mar 25, 2010 (BUSINESS WIRE) -- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that the last patient was enrolled and received the first dose in a 6-month, multicenter, international Phase 2 clinical trial of a novel version of inhaled ciprofloxacin (ARD-3150) in
Aradigm Announces Fourth Quarter 2009 and Full Year Financial Results
Mar 23, 2010
Net Loss is Reduced by 39% While Advancing Bronchiectasis Clinical Program
Aradigm Doses First Patient in Its Second Phase 2b Clinical Trial of Inhaled Liposomal Ciprofloxacin in Bronchiectasis Patients
Feb 23, 2010
HAYWARD, Calif., Feb 23, 2010 (BUSINESS WIRE) -- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that it dosed the first patient in the U.S. as part of its ORBIT-1 (Once-daily Respiratory Bronchiectasis Inhalation Treatment) trial, an international, randomized, double-blind,
Aradigm Receives $4 Million Milestone Payment Upon First Commercial Sale of SUMAVEL* DosePro*
Feb 04, 2010
HAYWARD, Calif., Feb 04, 2010 (BUSINESS WIRE) -- Aradigm Corporation (OTCBB:ARDM) (the "Company") announced today that it received the $4 million milestone payment from Zogenix, Inc. ("Zogenix") based upon the first commercial sale in the U.S. of SUMAVEL* DosePro* (sumatriptan injection)
Aradigm to Present at Biotech Showcase 2010 on January 12
Jan 06, 2010
HAYWARD, Calif., Jan 06, 2010 (BUSINESS WIRE) -- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that President and Chief Executive Officer Igor Gonda, Ph.D., will present at the Biotech Showcase 2010 on Tuesday, January 12, 2010, at 3:00 p.m. Pacific time.
Aradigm to Present at the Lippert/Heilshorn Life Sciences Virtual Conference on December 15
Dec 10, 2009
HAYWARD, Calif., Dec 10, 2009 (BUSINESS WIRE) -- Aradigm Corporation (OTCBB:ARDM) today announced that President and Chief Executive Officer Igor Gonda, Ph.D. will present to investors as part of the Lippert/Heilshorn & Associates Life Sciences On-line Forum on December 15, 2009 at 12:00 Noon
Aradigm Doses First Patient in Long-Term Phase 2 Study of a Novel Inhaled Ciprofloxacin Formulation for the Management of Respiratory Infections in Bronchiectasis
Nov 16, 2009
Study Will Explore the Long-Term Safety and Efficacy of Inhaled Ciprofloxacin in a Severe Respiratory Disease with Unmet Medical Needs
Aradigm Announces Third Quarter 2009 Financial Results
Nov 05, 2009
Inhaled Liposomal Ciprofloxacin Program is Progressing; Milestone Payment and Royalties Will Be Received Upon Zogenix Planned January 2010 Product Launch
Aradigm to Present at the 8th Annual BIO Investor Forum on October 28
Oct 22, 2009
HAYWARD, Calif., Oct 22, 2009 (BUSINESS WIRE) -- Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that President and Chief Executive Officer Igor Gonda, Ph.D., will present at the 2009 Annual BIO Investor Forum on Wednesday, October 28, 2009, at 12:30 p.m. Pacific time (3:30 p.m.
Aradigm Presents Data Demonstrating Significant Antibacterial Concentrations and Effects in Non-Cystic Fibrosis Bronchiectasis Patients Following Administration of its Once-Daily Inhaled Liposomal Ciprofloxacin
Sep 14, 2009
Aradigm is presenting results from its Phase 2a clinical trial in non-cystic fibrosis bronchiectasis patients at the 2009 European Respiratory Society (ERS) Annual Congress.Additionally, Aradigm is presenting summary data on the pharmacokinetics of its once-daily inhaled liposomal ciprofloxacin formulation (CFI) in CF patients and healthy volunteers.
Aradigm Announces Second Quarter 2009 Financial Results
Aug 06, 2009
HAYWARD, Calif., Aug 06, 2009 (BUSINESS WIRE) -- Aradigm Corporation (OTCBB: ARDM) (the "Company") today announced financial results for the second quarter and six months ended June 30, 2009. No revenue was recorded for the second quarter of 2009, compared with revenue of $54,000 for the second
Displaying 121 - 140 of 229
CONTACT NEWS & EVENTS LEGAL SITE MAP ©2018 Aradigm Corporation. All Rights Reserved.